Company Overview
About Superluminal Medicines
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
Business Model & Competitive Advantage
Superluminal's AI GPCR drug discovery platform addresses the conformational complexity that makes most GPCRs undruggable by conventional methods: GPCRs are membrane proteins that exist in multiple conformational states — their three-dimensional structure changes dynamically based on which signaling pathways are active, making it difficult to design small molecules that selectively bind one conformation (the therapeutically relevant one) without hitting off-target conformations that cause side effects. Superluminal's combination of AI-predicted protein dynamics (modeling GPCR conformational states across time), structural biology validation (cryo-EM and crystallography data to confirm binding modes), and generative chemistry (designing molecules that exploit the predicted binding pockets) enables rational drug design for GPCR targets that structure-based drug design methods fail on because the relevant binding conformation doesn't crystallize easily.
Competitive Landscape 2025–2026
In 2025, Superluminal competes in the AI drug discovery, GPCR therapeutics, and cardiometabolic drug development market with Schrödinger (NASDAQ: SDGR, computational drug design platform, $200M revenue), Recursion (NASDAQ: RXRX, AI drug discovery at scale, $400M+ raised), and Relay Therapeutics (NASDAQ: RLAY, protein dynamics drug design, $700M raised) for pharmaceutical partner AI-driven small molecule drug discovery and GPCR target development collaboration. Eli Lilly's $1.3B collaboration (in August 2025) validates Superluminal's platform at the highest tier of pharmaceutical partnership investment. NVIDIA NVentures' participation reflects AI computational infrastructure investment in the drug discovery application. RA Capital's Series A leadership provides deep biotech public market expertise. The 2025 strategy focuses on advancing the MC4R obesity program to IND filing, building the GPCR discovery pipeline for additional cardiometabolic targets under the Lilly collaboration, and expanding the platform to Class B/C GPCRs in neurological and inflammatory disease areas.
The Superluminal Medicines Story
Founders
Company Timeline
Major milestones in Superluminal Medicines's journey
Leadership Team
Meet the leaders behind Superluminal Medicines
Cony D'Cruz
Co-founded Superluminal in 2022 and leads the company as CEO. Oversees strategic direction, partnerships, and overall operations.
Ajay Yekkirala
Former postdoc at Harvard Medical School and Boston Children's Hospital. Previously co-founded Blue Therapeutics and served as VP and Head of Biology at RA Capital Management.
Yang-Ming Zhu
Leads engineering and technology development for Superluminal's AI-driven drug discovery platform.
Yamina A. Berchiche
Leads biological research programs and contributes to target validation and drug candidate development.
Marek Orzechowski
Leads computational chemistry efforts supporting AI-driven drug design and optimization.
Murco Ringnalda
Oversees operations and strategic execution across the organization.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Superluminal Medicines is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $1300M in revenue, Superluminal Medicines operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Compare Superluminal Medicines with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Superluminal Medicines? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Superluminal Medicines Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Superluminal Medicines vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →